

Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee
Summary of Main Points from the Meeting held on the 12th of March 2012

2. Minutes and Summary Notes from last meeting

The Minutes and Summary notes were approved and will be circulated.

3. Matters Arising

The committee noted the matters arising from the previous meeting.

4. New Medicines Applications

Formulary Applications

Additions

- **Eltrombopag 25mg and 50mg tablet for Chronic immune thrombocytopenic purpura**

Decision: Approved. Tariff Excluded Medicine. Individual Funding Request required.

The committee noted a decision by the Pharmacoeconomics board to approve eltrombopag 25mg and 50mg tablets as an individual funding request for chronic immune thrombocytopenic purpura.

Ex-Panel Requests

- **Solifenacin 10 mg tablet**

Decision: Approved. Tariff Included Medicine.

- **Nonoxinol (Gygel) Gel spermicide**

Decision: Approved. Tariff Included Medicine.

5. Medicines Management /Medicines Policy

- **Section 14 – Adverse Drug Reactions**

Approved update according to requirements in the Information Standards Notice (ISN) – New Standard 1582, which is an update on the previous advance notification relating to Yellow card ADR reporting..

- **Section 16 - Ward Openings & Closings**

Approved update according to Trust's new name under foundation status, current pharmacy management structure and to include items stored in a refrigerator.

- **Section 17 – Doctor's Own Prescriptions**

Approved updated to reflect the current pharmacy management structure.

- **Medicines Committee Terms of Reference**

Update Approved with a minor amendment.

The terms of reference have been updated to reflect current membership and proposed changes caused by the proposed Integrated North West London Formulary. The name of one of the divisions also required updating.

The committee discussed the proposed Integrated NWL Formulary to be in effect from the 1st of April 2012 and concerns were raised by clinicians as follows:

- members feel they have not been consulted on in a timely manner, with adequate notice for meetings with specialist clinicians
- process for additions or deletions to the NWL Formulary (i.e. the proposed NWL Drugs and Therapeutics Panel) not in place
- concerns about GPs changing therapy initiated by specialists in hospitals

The chairman agreed to write to Dr. Dr. Mark Sweeney, Chair, NWL Clinical Commissioning Group on behalf of the Medicines Committee to raise these concerns

6. NICE Guidance January & February 2012

- **TA 241 - Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant)**

Noted – update formulary status to reflect NICE Guidance.

- **TA243 - Follicular lymphoma - rituximab (review)**

Noted – update formulary status to reflect NICE Guidance.

- **TA242 - Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)**

No action – not applicable to C&W.

- **TA244 - Chronic obstructive pulmonary disease - roflumilast**

No action – not applicable to C&W.

- **TA245 - Venous thromboembolism - apixaban (hip and knee surgery)**

No action – apixaban is an option for treatment, however rivaroxaban is already on formulary for this indication.

- **TA246 - Venom anaphylaxis - immunotherapy pharmlagen**

**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee**

No action – not applicable to C&W

- **TA248 - Diabetes (type 2) - exenatide (prolonged release)**

Noted – update formulary status to reflect NICE Guidance.

- **TA247 - Rheumatoid arthritis - tocilizumab**

Noted – update formulary status to reflect NICE Guidance.

7. IVIG Update December 2011 & January 2012

There were 13 IVIG issues in February 2012, with 3 new requests a Kawasaki disease, Toxic epidermal necrolysis and idiopathic thrombocytopenic purpura (all red indications).

8. Items for Noting

The committee noted the following items:

- HIV Drugs Sub-committee Minutes January 2012
- CD Occurrence Report for Quarter 3 2011/12 (October-December 2011)
- Statin and ACEI vs ARB Audit February 2012
- PGD Tracker
- Unlicensed medicinal products list update

9. Papers to go to the Trust Quality Committee

The following papers should be sent to the Trust Quality Committee

- Medicines Committee February 2012 Summary Notes
- CD Occurrence Report for Quarter 3 2011/12 (October-December 2011)
-

10. Date of the next meeting

Next Meeting: Monday 16th of April 2012 8.00am – 9.00am Board Room, Lower Ground Floor

Closing date for papers: Friday 23rd of March 2012